Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05402345 · ClinicalTrials.gov registry record · Phase 2
A Study of GlcNAc on Tear Production in NGLY1-CDDG
A Phase 2 study of NGLY1 Deficiency, sponsored by Eva Morava-Kozicz.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT05402345 is a Phase 2 study of NGLY1 Deficiency that is active but no longer recruiting, run by Eva Morava-Kozicz. The registered enrollment target is 18 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05402345, a Phase 2 study of NGLY1 Deficiency, is active but no longer recruiting, sponsored by Eva Morava-Kozicz.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG GlcNAc-GlcN
Study Locations (2)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05402345
The ClinicalTrials.gov registry entry for NCT05402345 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eva Morava-Kozicz, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NGLY1 Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05402345 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT05402345 about?
NCT05402345 is a clinical study titled "A Study of GlcNAc on Tear Production in NGLY1-CDDG". In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
What is the current status of trial NCT05402345?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2025-01-24. Estimated completion is 2026-12.
What conditions does trial NCT05402345 study?
This clinical trial studies the following conditions: NGLY1 Deficiency.
What interventions are being tested in trial NCT05402345?
The interventions under investigation include: Placebo (OTHER), GlcNAc-GlcN (DRUG).
Who is sponsoring clinical trial NCT05402345?
This trial is sponsored by Eva Morava-Kozicz, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05402345 being conducted?
This trial has 2 study locations across Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NGLY1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.